Labshake search
Citations for Haematologic Technologies :
1 - 8 of 8 citations for B Cell Activating Factor BAFF TNFSF13B Antibody since 2019
Citations are collected from bioRxiv only, the total number of publications could be much larger.
-
bioRxiv - Bioengineering 2022Quote: ... Human coagulation Factor X (hFX) (Haematologic Technologies) was added to diluted vectors at a final concentration of 8 μg/mL ...
-
bioRxiv - Biochemistry 2019Quote: ... factor V (Haematologic Technologies Inc., Essex Junction, VT), recombinant factor IX (Benefix® ...
-
bioRxiv - Bioengineering 2020Quote: ... and Factor Xa were purchased from Haematologic Technologies, Inc ...
-
bioRxiv - Bioengineering 2020Quote: Positive controls of Innovin (Siemens Healthcare Diagnostics, Germany) or Factor IXa (Haematologic Technologies, VT, USA) were used separately ...
-
bioRxiv - Biochemistry 2021Quote: Plasma coagulation factors and 25:75 PS:PC (phosphatidylserine-phosphatidylcholine) phospholipids were purchased from Haematologic Technologies Incorporated (Vermont ...
-
bioRxiv - Microbiology 2021Quote: ... Factor X and prothrombin-deficient plasma were obtained from Haematologic Technologies (#FX-ID and #FII-ID). Russell’s Viper Venom test was performed with 10 µg/ml snake venom from Vipera russelli (RVV ...
-
bioRxiv - Pathology 2020Quote: ... membranes were incubated overnight at 1:2000 in primary antibody (Anti-murine Prothrombin, Haematologic Technologies Inc, Essex Junction, VT) followed by corresponding secondary antibody conjugated to horseradish peroxidase ...
-
bioRxiv - Pathology 2020Quote: ... ELISA and immunoblot antibodies were validated using species-specific positive (purified species-specific protein; Haematologic Technologies, Inc, Essex Juntion, VT) and non-specific protein negative controls ...